These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 23239178

  • 1. Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism.
    Hu ZY, Parker RB, Herring VL, Laizure SC.
    Anal Bioanal Chem; 2013 Feb; 405(5):1695-704. PubMed ID: 23239178
    [Abstract] [Full Text] [Related]

  • 2. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.
    Laizure SC, Parker RB, Herring VL, Hu ZY.
    Drug Metab Dispos; 2014 Feb; 42(2):201-6. PubMed ID: 24212379
    [Abstract] [Full Text] [Related]

  • 3. Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers.
    Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, Schaefer O.
    Drug Metab Dispos; 2014 Feb; 42(2):250-6. PubMed ID: 24212377
    [Abstract] [Full Text] [Related]

  • 4. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
    Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ.
    Biochem Pharmacol; 2016 Nov 01; 119():76-84. PubMed ID: 27614009
    [Abstract] [Full Text] [Related]

  • 5. Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation.
    Laizure SC, Chen F, Farrar JE, Ali D, Yang B, Parker RB.
    Drug Metab Pharmacokinet; 2022 Dec 01; 47():100479. PubMed ID: 36375226
    [Abstract] [Full Text] [Related]

  • 6. Development and validation of LC-MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma.
    Nouman EG, Al-Ghobashy MA, Lotfy HM.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May 01; 989():37-45. PubMed ID: 25797721
    [Abstract] [Full Text] [Related]

  • 7. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate.
    Udomnilobol U, Jianmongkol S, Prueksaritanont T.
    Drug Metab Dispos; 2023 Sep 01; 51(9):1216-1226. PubMed ID: 37230768
    [Abstract] [Full Text] [Related]

  • 8. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
    Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W.
    Drug Metab Dispos; 2008 Feb 01; 36(2):386-99. PubMed ID: 18006647
    [Abstract] [Full Text] [Related]

  • 9. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta.
    Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H, Koren G.
    Obstet Gynecol; 2014 Jun 01; 123(6):1256-1261. PubMed ID: 24807346
    [Abstract] [Full Text] [Related]

  • 10. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
    Li YZ, Gong GQ, Yang WH, Wang XH, Jiang ML, Zhou Y, Yang XZ, Xu YG, He GW.
    Thromb Res; 2013 May 01; 131(5):425-35. PubMed ID: 23535565
    [Abstract] [Full Text] [Related]

  • 11. Lymphatic Uptake of a Highly Lipophilic Protease Inhibitor Prodrug from a Lipid-Based Formulation is Limited by Instability in the Intestine.
    Xie Y, Lu Z, Styles IK, Reddiar SB, Phillips ARJ, Windsor JA, Porter CJH, Han S, Trevaskis NL.
    J Pharm Sci; 2024 Aug 01; 113(8):2342-2351. PubMed ID: 38582284
    [Abstract] [Full Text] [Related]

  • 12. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
    Merali Z, Ross S, Paré G.
    Drug Metabol Drug Interact; 2014 Aug 01; 29(3):143-51. PubMed ID: 24988246
    [Abstract] [Full Text] [Related]

  • 13. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
    Zhao Y, Hu ZY.
    Br J Pharmacol; 2014 Feb 01; 171(4):1043-53. PubMed ID: 24283665
    [Abstract] [Full Text] [Related]

  • 14. Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism.
    Wu WN, McKown LA, Reitz AB.
    Eur J Drug Metab Pharmacokinet; 2006 Feb 01; 31(4):277-83. PubMed ID: 17315539
    [Abstract] [Full Text] [Related]

  • 15. 5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate.
    Tsujii K, Hattori T, Imaoka A, Akiyoshi T, Ohtani H.
    J Pharm Sci; 2018 May 01; 107(5):1430-1433. PubMed ID: 29291414
    [Abstract] [Full Text] [Related]

  • 16. Quantitative estimation of circulating metabolites without synthetic standards by ultra-high-performance liquid chromatography/high resolution accurate mass spectrometry in combination with UV correction.
    Yang Y, Grubb MF, Luk CE, Humphreys WG, Josephs JL.
    Rapid Commun Mass Spectrom; 2011 Nov 15; 25(21):3245-51. PubMed ID: 22006386
    [Abstract] [Full Text] [Related]

  • 17. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
    Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Schaefer O.
    Drug Metab Dispos; 2014 Feb 15; 42(2):257-63. PubMed ID: 24212378
    [Abstract] [Full Text] [Related]

  • 18. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
    Douxfils J, Dogné JM, Mullier F, Chatelain B, Rönquist-Nii Y, Malmström RE, Hjemdahl P.
    Thromb Haemost; 2013 Sep 15; 110(3):543-9. PubMed ID: 23783171
    [Abstract] [Full Text] [Related]

  • 19. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.
    Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T.
    J Pharm Biomed Anal; 2012 Jan 25; 58():152-6. PubMed ID: 21996066
    [Abstract] [Full Text] [Related]

  • 20. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
    Lang J, Vincent L, Chenel M, Ogungbenro K, Galetin A.
    Eur J Pharm Sci; 2021 Oct 01; 165():105932. PubMed ID: 34260894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.